An observational study in MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and NAFLD, sponsored by University of California, San Diego. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of California, San Diego · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego — 1 open to participants now, 3 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · University of California, San Diego.
Among the 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego, this one is the only one that started in 2026, is one of 6 observational ones, and was the 14th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →1 of the 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego is open now, in 1 country. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 5+ · Healthy volunteers
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 50 across the 8 interventional studies, 40 across the 6 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
2 of the studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06005012University of California, San DiegoSemaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | 2026-12-31 |
| NCT06661538University of California, San DiegoImplementing Food Referrals for Equity and Sustained Health | 2027-06-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Non-alcoholic Fatty Liver Disease by University of California, San Diego, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.
In this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.
Study participants will be asked to complete a one-time visit which includes:
Adults with known or clinically suspected MASLD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single arm study in which all participants undergo the same research procedures.
Diagnostic Test: LiverScope® exam · Diagnostic Test: MR exam · Diagnostic Test: Blood draw · Other: Body measurements · Other: Questionnaire
Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
Also known as: MRI, MRI exam
A blood sample of approximately 10 mL will be collected for routine laboratory tests including complete blood count (CBC) and comprehensive metabolic panel (CMP).
Height, weight, waist circumference, and hip circumference will be measured.
A questionnaire will be administered to collect demographic information (including age, sex, race, and ethnicity), and medical and social history (including alcohol use, tobacco use, history of diabetes, history of liver disease, and current medications).
Agreement of LiverScope® measurements compared to conventional MR
Assessment of agreement between LiverScope® measurements and conventional MR measurements in the liver.
Time frame: Up to 3 months
Repeatability and reproducibility of LiverScope® measurements
Estimation of repeatability and reproducibility coefficients of liver measurements made by LiverScope®.
Time frame: Up to 3 months
Liver T1, T2, and stiffness measurements
Using MR spectroscopy, T1 and T2 of liver tissue will be measured. Liver stiffness will be measured by MR Elastography. These data will enable confounder testing.
Time frame: Up to 3 months.
Plan to share: Yes — This is an NIH SBIR study. De-identified coded data will be shared as per grant application.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: One year after completion
Access criteria: Public
Data sharing details ↗ · library.ucsd.edu
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Aug 2026, 3 months.
Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's 3 months is below that.
Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
University of California, San Diego →